A major clinical trial is investigating whether existing medicines for diabetes and ADHD could help slow the symptoms of Alzheimer's disease. The AD-SMART study will initially test metformin, used for type 2 diabetes, and atomoxetine, prescribed for ADHD, to determine whether they improve memory, thinking and everyday functioning. Researchers believe both drugs may help reduce brain inflammation associated with neurodegeneration. Unlike traditional studies, the trial will test several treatments simultaneously, allowing ineffective medicines to be replaced quickly and potentially accelerating discoveries. Around 1,200 people with mild to moderate Alzheimer's will participate in more than thirty locations. Angela Bucksey, 67, from Cambridgeshire, became the first participant, describing the opportunity as a way of fighting back against her diagnosis. Alzheimer's affects approximately 600,000 people across Britain, placing enormous emotional and practical pressures on families. Andy Burnham, whose father recently died from the disease, welcomed the research. Scientists hope the first results, expected in 2030, will identify promising treatments that improve patients' quality of life.